Immunis.AI Achieves Development Milestones and Additional Financing

ROYAL OAK, Mich.–(BUSINESS WIRE)–Immunis.AI, Inc., an immunogenomics platform company developing noninvasive blood-based tests to optimize patient care, today announced the close of additional financing that brings its total raised to $40 million to date for the ongoing development of its proprietary Intelligentia immunogenomic platform. The additional funding comes on the heels of successful completion of key development milestones, including three pivotal studies of the Intelligentia platform. Funding will support further validation and commercialization of the company’s first molecular test in prostate cancer and will also be used to expand development of new tests in breast, colon, lung cancer and other cancers.

The Intelligentia liquid biopsy platform enables a highly sensitive method for the detection and grading of early-stage cancer and other diseases using a single blood sample. The platform is used to identify and interrogate novel disease-specific biomarkers as well as biomarkers indicative of the immune response to the disease.

“Immunis has developed a platform that harnesses the power of the immune system, achieving potent signal enrichment using proprietary methods and advanced machine learning,” said Harry Stylli, Ph.D., Executive Chairperson of the Board at Immunis.AI. “With the recently achieved major milestones, the company is poised to deliver on its core mission to improve early detection and patient outcomes.”

“We are grateful for the continuing support of our investors, who share our excitement about the potential of our proprietary immunogenomic platform to transform patient care paradigms,” said Christopher Thibodeau, President & CEO of Immunis.AI. “We look forward to reporting results from our pivotal studies in prostate cancer and to delivering tests to better aid in the diagnosis and treatment of patients early, when there is the greatest opportunity for cure.”

The successful completion of milestones triggered the final tranche of new capital received over the last several months and positions the company to capitalize on the strong performance of the Intelligentia platform, to develop new pan cancer and disease surveillance tests, and to further advance commercial readiness of its lead test for the active surveillance of prostate cancer. The financing was led by Savitr Capital, LLC with participation from existing investors and management.

About Immunis.AI, Inc.

IMMUNIS.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology and individualized assessment. The Intelligentia platform combines the power of the immune system, RNAseq technology and Machine Learning (ML) for the development of disease-specific signatures. This proprietary method leverages the immune system’s surveillance apparatus to overcome the limitations of circulating tumor cells (CTCs) and cell free DNA (cfDNA). The platform improves detection of early-stage disease, at the point of immune-escape, when there is the greatest opportunity for cure. For more information, please visit our website: https://immunis.ai/

Contacts

Media Contact: Devin Osting at devinosting@ententeinc.com
Investor Contact: Geoffrey Erickson at investor.relations@immunis.ai